Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SP-104 vs Immediate Release Naltrexone in Healthy Adults
NCT04958876Phase 1Completed
- Sponsor
- Scilex Holding
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naltrexone hydrochloride delayed-release in fibromyalgia (FM) (2 arms), sponsored by Scilex Holding. Primary endpoint: Incidence of treatment emergent adverse events at 1 week. Started Oct 2021; status: completed.
02
Drugs
naltrexone hydrochloride delayed-release
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04958876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958876.